Analysis of engraftment and differentiation of HSCs and proT2-cells in the BM of immunodeficient mice. (A) Percentage of human CD45⁺HLA-A2⁺ (left), CD19 (middle), and CD33 (right) HSC-derived engraftment at 3 to 6 weeks, and 9 to 12 weeks after intrahepatic injection of neonatal NSG mice receiving either HSCs (white) or HSCs with proT2-cells (black). (B) Flow cytometric analysis of CD45 vs HLA-A2, and CD19 and CD33 on CD45⁺HLA-A2⁺–gated cells in the BM at 6 weeks postintrahepatic injection. Table 2 shows the number of mice analyzed. The results shown are representative of at least 3 independent experiments.